Description

PIRFENEX 801 MG (1X10)

Indications

PIRFENEX (pirfenidone) is an antifibrotic medication indicated for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by the accumulation of fibrotic tissue in the lungs, leading to decreased lung function and respiratory failure. By targeting the underlying mechanisms of fibrosis, PIRFENEX aims to slow disease progression and improve quality of life in affected individuals.

Mechanism of Action

Pirfenidone exhibits a multifaceted mechanism of action that involves the modulation of several pathways implicated in the fibrotic process. It is known to inhibit the synthesis of transforming growth factor-beta (TGF-β), a key cytokine that promotes fibrosis. Additionally, pirfenidone has antioxidant properties, which help to reduce oxidative stress and inflammation in the lungs. By targeting these pathways, PIRFENEX helps to decrease the proliferation of fibroblasts and the deposition of extracellular matrix components, thereby mitigating the fibrotic response in the lungs.

Pharmacological Properties

PIRFENEX is a small molecule with a molecular weight of 186.19 g/mol. It is administered orally and is well absorbed in the gastrointestinal tract. The pharmacokinetics of pirfenidone shows a peak plasma concentration occurring approximately 4 to 6 hours after administration. The drug has a half-life of about 2 to 4 hours, necessitating multiple daily doses to maintain therapeutic levels. Pirfenidone is primarily metabolized in the liver via the cytochrome P450 system, particularly CYP1A2, and is eliminated through both renal and fecal routes.

Contraindications

PIRFENEX is contraindicated in patients with a known hypersensitivity to pirfenidone or any of the excipients in the formulation. Additionally, it should not be used in patients with severe hepatic impairment, as the drug’s metabolism may be significantly affected, leading to increased risk of toxicity. Caution is advised in patients with renal impairment, and the use of PIRFENEX should be closely monitored in such cases.

Side Effects

Common side effects associated with the use of PIRFENEX include gastrointestinal disturbances such as nausea, diarrhea, and anorexia. Other reported side effects include fatigue, rash, and liver enzyme elevations. Serious adverse effects may include hepatotoxicity and hypersensitivity reactions. Patients should be monitored regularly for liver function tests, especially during the initial months of therapy, to detect any potential liver-related complications early.

Dosage and Administration

The recommended starting dose of PIRFENEX is 267 mg taken three times daily, totaling 801 mg per day. It is important to take the medication with food to enhance absorption and minimize gastrointestinal side effects. Dosage adjustments may be necessary based on individual tolerance and the presence of side effects. If patients experience significant adverse reactions, a dose reduction or temporary discontinuation may be warranted. It is crucial for patients to adhere to the prescribed regimen and consult their healthcare provider before making any changes to their dosage.

Interactions

PIRFENEX may interact with other medications, particularly those that are metabolized by the liver. Co-administration with strong CYP1A2 inhibitors, such as ciprofloxacin and fluvoxamine, can increase pirfenidone levels, potentially leading to increased toxicity. Conversely, inducers of CYP1A2, such as rifampicin and carbamazepine, may reduce the efficacy of PIRFENEX by decreasing its plasma concentration. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Patients taking PIRFENEX should be monitored for signs of liver dysfunction, as elevated liver enzymes can occur. Regular liver function tests are recommended, particularly during the first few months of treatment. Additionally, caution should be exercised in patients with a history of significant liver disease or those taking other hepatotoxic medications. Because of the potential for gastrointestinal side effects, patients should be advised on dietary modifications that may help alleviate symptoms. It is also important to assess patients for any signs of hypersensitivity reactions, which may necessitate discontinuation of therapy.

Clinical Studies

Clinical studies have demonstrated the efficacy of PIRFENEX in slowing the progression of idiopathic pulmonary fibrosis. In a pivotal Phase III trial, patients treated with pirfenidone showed a significant reduction in the decline of forced vital capacity (FVC) compared to placebo. Additionally, improvements in quality of life measures were noted, indicating a positive impact on patients’ functional status. Long-term follow-up studies have also suggested that pirfenidone may improve survival rates in patients with IPF, further supporting its role as a cornerstone therapy in this challenging condition.

Conclusion

PIRFENEX 801 MG (1X10) represents an important therapeutic option for patients suffering from idiopathic pulmonary fibrosis. With its unique mechanism of action and demonstrated efficacy in clinical trials, it offers hope for slowing disease progression and improving quality of life. However, careful monitoring for side effects and interactions is essential to ensure patient safety and optimize treatment outcomes. As with any medication, it is vital for patients to engage in open communication with their healthcare providers regarding their treatment plan.